Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14254916 | 0.85 | NPC1 (0.61) | HDAC6ALDH1A1PKMNPC1RAB9A | |
| SCHEMBL18630924 | 0.84 | NPC1 (0.55) | HDAC3HDAC1HDAC4HDAC6ALDH1A1 | |
| SCHEMBL28760659 | 0.84 | NPC1 (0.55) | HDAC3HDAC1HDAC4HDAC6ALDH1A1 | |
| SCHEMBL18630728 | 0.84 | NPC1 (0.55) | HDAC3HDAC1HDAC4HDAC6ALDH1A1 | |
| SCHEMBL18630923 | 0.84 | NPC1 (0.55) | HDAC3HDAC1HDAC4HDAC6ALDH1A1 | |
| SCHEMBL140038 | 0.84 | SMN1; SMN2 (0.67) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL181181 | 0.83 | ALDH1A1 (0.57) | ALDH1A1PKMNPC1RAB9AMEN1 | |
| SCHEMBL8072288 | 0.82 | LOXL2 (0.53) | HDAC6ALDH1A1MEN1EPHX2KMT2A | |
| SCHEMBL505546 | 0.81 | ALDH1A1 (0.63) | ALDH1A1RAB9AMEN1EPHX2KMT2A | |
| SCHEMBL5072982 | 0.81 | POLB (0.58) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957042-B | Synthesis process of 2, 2-trifluoroacetamidine | 苏州莱克施德药业有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-114957042-A | Synthesis process of 2,2, 2-trifluoroacetamidine | 苏州莱克施德药业有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114957042-B | Synthesis process of 2, 2-trifluoroacetamidine | 苏州莱克施德药业有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114957042-B | Synthesis process of 2, 2-trifluoroacetamidine | 苏州莱克施德药业有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118084731-A | Synthesis method of trifluoroacetamidine | 上海予君生物科技发展有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-114957042-A | Synthesis process of 2,2, 2-trifluoroacetamidine | 苏州莱克施德药业有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114957042-A | Synthesis process of 2,2, 2-trifluoroacetamidine | 苏州莱克施德药业有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| WO-2016167511-A2 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2016-10-20 | — | — | WO | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-8022062-B2 | 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022062-B2 | 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022062-B2 | 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | HDAC3 694/4885HDAC1 1188/4885HDAC4 959/4885 |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | ALK, NPM1, EML4 | HDAC3 3829/4885HDAC1 3925/4885HDAC4 2699/4885 |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | HDAC3 1457/4885HDAC1 2361/4885HDAC4 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.